NY-PHILIP-MORRIS-INTL
24.9.2020 21:22:05 CEST | Business Wire | Press release
André Calantzopoulos, CEO of Philip Morris International (PMI) (NYSE: PM), today delivered high-level remarks at the 2020 Concordia Annual Summit . Calantzopoulos discussed the impact that uncertainty, polarization, hyperpartisanship, and ideology are having on international efforts to overcome pressing global issues. He called for science to be protected from politicization and highlighted the importance of developing open dialogues based on factual scientific objectivity. Calantzopoulos shared PMI’s belief that with the right regulatory encouragement and support from civil society, cigarette sales can end within 10 to 15 years in many countries.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
Excerpts of the remarks by André Calantzopoulos follow:
“Reflecting on the state of our world today and the challenges ahead, four words come to mind: Uncertainty . Polarization. Hyperpartisanship. Ideology.
“These words are not new, but with the COVID crisis, they have gained prominence, moving beyond traditionally contentious sectors such as ours and into the mainstream.
“The lockdowns that sent us into our homes earlier this year, the continued uncertainty we all feel, and the immense socioeconomic pressure caused by the pandemic have increased tensions and reinforced the polarization of both private views and the public discourse.
“And while these past months have revealed how much can be accomplished when people work together, the tendency of individuals to put their self-centered impulses ahead of community wellness remains on display.
“Divisiveness—a binary choosing of sides—not only hinders progress but threatens to thwart it.
“Maybe there is no silver-bullet solution—but to focus on respect for and adherence to facts, dialogue, inclusion, and science could help immensely. It is not enough, however, to simply say ‘follow the facts and the science’ and expect progress to unfold. COVID-19 is just the latest example that proves a tragic truth: Science can be, and is being, weaponized to suit narrow agendas. Science and facts are being held hostage—and distorted—by politics, and people are suffering as a result.
“As a society, we are experiencing a confluence of global existential threats. These threats require collective, multilateral discussions and cooperation—and that can only be achieved through a commitment to open dialogue.
“Absent a commitment to factual scientific objectivity—free of agenda-driven politics—we risk the very real and terrifying prospect of vaccine nationalism, an inability to tackle climate change at scale, and a narrowed chance of delivering solutions that create a fairer and more equitable world.
“In a global world, in a global economic and human system, whether we like it or not, there is no solution in isolation. Individual governments or companies alone cannot bring the necessary change. If we want to make the United Nations Sustainable Development Goals a reality, if we want to protect our populations from the pandemic, including implementing a viable vaccine, we must work together. And most important, we must involve the 7.8 billion people on this planet. How do we do this? We tell them what the real problems are—offering the full facts; we propose solutions they can adopt or adapt; and we incentivize them to act in accordance with this new knowledge. We won’t succeed by keeping them in the dark, by confusing them, or by misleading them.
“Being at the helm of the largest multinational tobacco company as it transforms to deliver a smoke-free future, I experience firsthand how detrimental polarization is to making real progress—in this case, progress in eradicating smoking. And, as a reminder, this concerns more than 1 billion men and women who smoke around the world.
“Today, science-based, innovative products that do not involve combustion offer a better alternative for those men and women who would otherwise continue to smoke. To be clear: These products are not risk-free. And the best choice is never to start smoking or to quit tobacco and nicotine altogether. But for those adults who would otherwise continue to smoke, scientifically validated smoke-free products are a much better choice than cigarettes.
“A future in which cigarettes are obsolete is within reach. In fact, with the right regulatory encouragement and support from civil society, we believe cigarette sales can end within 10 to 15 years in many countries. Yes, that’s right: an end to cigarettes within 10 to 15 years in many countries.
“Unfortunately, political agendas and ideology are slowing progress and keeping millions of people uninformed. Rather than holding an evidence-based conversation on how best to regulate these innovative products to help adult smokers leave cigarettes behind, we are often faced with an ideologically driven resistance from some public health organizations and some NGOs. These organizations allow disinformation to appear as legitimate science. They put dogma before data, and they expend more energy on attacking a company than on helping the human beings who should be at the center of the debate.
“Poorly executed scientific studies, skewed results shaped by bias, and misleading media headlines are now the norm.
“What is the result? Many adults who smoke are confused about these better alternatives and so continue to use cigarettes—the most harmful way of consuming nicotine. This is inexcusable. We must ask: Who will take responsibility for denying these adults access to and accurate information about science-backed innovations? Who will be held responsible for the real-world consequences of dogmatic thinking?
“The issues created by uncertainty, polarization, hyperpartisanship, and ideology are not unique to the tobacco sector. From climate change to food security, we need fact-based conversations and a collaborative, multinational, multi-stakeholder approach to deliver real change. The public has a right to decision-making and information based in science. We cannot allow politically driven, well-funded individuals to prevent the world’s citizens from learning about and accessing smart solutions. Whether we are talking about vaccines, carbon emissions, or tobacco harm reduction, we need science, not rhetoric, to inform policies and regulations.
“Science unites. It has the power to open borders and minds and bring progress. It can propel innovation.
“For Philip Morris International, science has changed our company and is transforming our industry. I am proud to come before you today to say that, already, more than 11.2 million people have switched to our main smoke-free product and stopped smoking . Many more have switched to other smoke-free alternatives that are better than continued smoking. This is a profound public health achievement.
“Governments across the world—in Greece, New Zealand, the United Kingdom, and beyond—are beginning to validate the role better alternatives to continued smoking can play. Earlier this year, the U.S. Food and Drug Administration authorized our electronically heated tobacco system, IQOS , as a modified risk tobacco product. In doing so, the agency found that an exposure modification order is ‘appropriate to promote the public health .’
“But a smoke-free future is not yet guaranteed. Ridding the world of cigarettes will require adherence to science, objectivity, collaboration, and a commitment to accelerate information to the people most directly concerned.
“Many years ago, our industry was challenged to create a better alternative to cigarettes. PMI answered that call. We have transformed our entire company to devise and produce scientifically substantiated better products with the aim of delivering a smoke-free future. Science, data, and fact have led us here.
“People who smoke are responding to our efforts. With the right regulations and related information, they could switch out of cigarettes much faster. Let’s put these people—not politics—at the center of policymaking.
“Science secures progress. It secures solutions. It brings hope at a time when global challenges are so great they threaten to overwhelm. We should not allow science to be politicized and polarized.”
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the U.S. under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2020, PMI estimates that approximately 11.2 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 57 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION14.7.2026 14:00:00 CEST | Press release
Non-arteritic anterior ischemic optic neuropathy (NAION) is a loss of blood flow to the optic nerve which causes spontaneous and rapid vision loss, for which there are currently no FDA-approved treatments. Given the substantial unmet need for effective treatments in NAION, in October 2025, Dompé was awarded a Commissioner’s National Priority Review Voucher (CNPV) by the US FDA to accelerate a potential Biologics License Application for intranasal nerve growth factor (NGF) in NAION. Dompé, a biopharmaceutical company with operations in Italy and the US, announced the first patient has been enrolled in a Phase 3 study of cenegermin-bkbj for the treatment of non-arteritic anterior ischemic neuropathy (NAION). Involving more than 130 centers globally, the Phase 3 trial, “Galassia-NAION-301” is a multicenter, double-blind study comparing cenegermin-bkbj against placebo in improving vision loss caused by NAION. “Our NGF R&D program continues to accelerate with our third clinical study of 202
CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening14.7.2026 14:00:00 CEST | Press release
New indication in the European Union and the UK offers alternative method of screening especially for women who are not currently participating Hologic, Inc. announced today that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260714358586/en/ Hologic’s Aptima® HPV Assay and Aptima Multitest Specimen Collection Kit Cervical cancer is the fourth most common cancer in women but is largely preventable through HPV vaccination and regular screening.1 Evidence shows that organized screening and early detection reduces deaths from cervical cancer, with mortality reduction rates in Europe ranging from 41% to 92%.2 However, even in countries with an established cervical screening program, screening participation rates vary widely, from 25%
Cover Genius Raises USD $100M Backed by Vista Credit Partners, Reaching USD $1.9 Billion Valuation as it Advances AI-First Platform and Global Expansion14.7.2026 14:00:00 CEST | Press release
Accelerating the AI roadmap and next era of embedded protection Cover Genius, the global infrastructure for embedded protection, today announced a USD $100M capital raise, backed by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on enterprise software. The raise values the business at USD $1.9 billion, advancing a new chapter for the company. Cover Genius operates a B2B2C embedded protection platform that connects 200+ partners with 50+ global insurance carriers to protect over 70 million end customers at the point of sale across travel, retail, ticketing and logistics. Unlike traditional insurers, Cover Genius dynamically adapts product design, pricing, and presentation in real time to match each merchant's unique customer journey and geography mix. “We’ve spent more than a decade building the trust layer the world’s largest digital companies rely on to protect their customers. Today’s raise is about broadening possibilities: movin
Esri to Debut the Power of Where Collection at 2026 Esri User Conference14.7.2026 14:00:00 CEST | Press release
New Titles Expand on Landmark Work to Showcase How GIS Drives Better Decisions Across Water and Land Management Esri will debut the Power of Where Collection at the 2026 Esri User Conference. The collection builds on the 2024 book The Power of Where by Jack Dangermond, extending its ideas into real-world GIS applications. New titles in the collection highlight GIS uses in water forecasting, land records, infrastructure planning, and economic development. The series demonstrates how spatial analysis helps organizations address challenges including sustainability, climate resilience, and governance. Esri, the global leader in location intelligence, will debut the Power of Where Collection at the 2026 Esri User Conference in July. The collection builds on the ideas introduced in The Power of Where: A Geographic Approach to the World's Greatest Challenges, by Esri president Jack Dangermond, published in 2024. The new collection expands these foundational concepts into focused, real-world a
Esri Introduces ArcGIS for ServiceNow, Bringing Location Intelligence into Everyday Enterprise Workflows14.7.2026 14:00:00 CEST | Press release
New Integration Connects Platforms, Enabling Real-Time Mapping Directly Within Existing Systems Esri is launching ArcGIS for ServiceNow, an integration that connects ServiceNow, the AI control tower for business reinvention, with ArcGIS, bringing location intelligence into everyday enterprise workflows. The solution supports organizations across commercial, government, health care, utilities, energy, telecom, and other sectors. Users can visualize incidents, assets, work orders, facilities, and other business data on maps in real time within ServiceNow or ArcGIS, improving decision-making and operational efficiency. The integration eliminates data duplication by enabling seamless data sharing between systems, bridging business records with geographic context. ArcGIS for ServiceNow will debut in beta shortly after Esri User Conference. Esri, the global leader in geographic information system (GIS) technology, has announced ArcGIS for ServiceNow, connecting the two platforms for the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
